BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC, Rosenfeld M, Starner T, Retsch-bogart G, Chmiel J, Orenstein D, Milla C, Rubenstein R, Walker S, Cornell A, Asfour F, Black P, Colombo J, Froh D, Mccolley S, Ruiz F, Quintero D, Casey A, Mueller G, Flume P, Livingston F, Rock M, O'sullivan B, Schmidt H, Lahiri T, Mcnamara J, Chidekel A, Sass L, Keens T, Schaeffer D, Solomon M, Chilvers M, Lands L, Junge S, Griese M, Staab D, Pressler T, van Koningsburggen-rietschel S, Naehrlich L, Reid A, Balfour-lynn I, Urquhart D, Lee T, Munck A, Gaudelus IS, De Boeck C, Reix P, Malfroot A, Bui S, Selvadurai H, Robinson P, Wainwright C, Clements B, Hilton J, Hjelte L. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine 2017;5:557-67. [DOI: 10.1016/s2213-2600(17)30215-1] [Cited by in Crossref: 166] [Cited by in F6Publishing: 52] [Article Influence: 33.2] [Reference Citation Analysis]
Number Citing Articles
1 Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Ivacaftor in People with Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation. Ann Am Thorac Soc 2021;18:433-41. [PMID: 33095038 DOI: 10.1513/AnnalsATS.202006-659OC] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
2 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ringshausen FC, Hellmuth T, Dittrich AM. [Evidence-based treatment of cystic fibrosis]. Internist (Berl) 2020;61:1212-29. [PMID: 33201261 DOI: 10.1007/s00108-020-00896-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr 2018;30:372-7. [PMID: 29538046 DOI: 10.1097/MOP.0000000000000627] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
5 Robinson PD, Jensen R, Seeto RA, Stanojevic S, Saunders C, Short C, Davies JC, Ratjen F. Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials. J Cyst Fibros 2021:S1569-1993(21)01374-6. [PMID: 34526221 DOI: 10.1016/j.jcf.2021.08.033] [Reference Citation Analysis]
6 Karanth TK, Karanth VKLK, Ward BK, Woodworth BA, Karanth L. Medical interventions for chronic rhinosinusitis in cystic fibrosis. Cochrane Database Syst Rev 2019;10:CD012979. [PMID: 31642064 DOI: 10.1002/14651858.CD012979.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther 2019;13:2405-12. [PMID: 31409974 DOI: 10.2147/DDDT.S153719] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cruz DF, Mitash N, Farinha CM, Swiatecka-Urban A. TGF-β1 Augments the Apical Membrane Abundance of Lemur Tyrosine Kinase 2 to Inhibit CFTR-Mediated Chloride Transport in Human Bronchial Epithelia. Front Cell Dev Biol 2020;8:58. [PMID: 32117984 DOI: 10.3389/fcell.2020.00058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Balázs A, Mall MA. Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis. Front Pharmacol 2018;9:1112. [PMID: 30327603 DOI: 10.3389/fphar.2018.01112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
10 Lauwers E, Belmans D, Mignot B, Ides K, Van Hoorenbeeck K, Snoeckx A, Van Holsbeke C, Nowé V, Van Braeckel E, De Backer W, De Backer J, Verhulst S. The short-term effects of ORKAMBI (lumacaftor/ivacaftor) on regional and distal lung structures using functional respiratory imaging. Ther Adv Respir Dis 2021;15:17534666211046774. [PMID: 34541955 DOI: 10.1177/17534666211046774] [Reference Citation Analysis]
11 Horsley AR, Alrumuh A, Bianco B, Bayfield K, Tomlinson J, Jones A, Maitra A, Cunningham S, Smith J, Fullwood C, Pandyan A, Gilchrist FJ. Lung clearance index in healthy volunteers, measured using a novel portable system with a closed circuit wash-in. PLoS One 2020;15:e0229300. [PMID: 32097445 DOI: 10.1371/journal.pone.0229300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ratjen F, Jensen R, Klingel M, McDonald R, Moore C, Benseler N, Wilson D, Stanojevic S. Effect of changes in tidal volume on multiple breath washout outcomes. PLoS One 2019;14:e0219309. [PMID: 31269068 DOI: 10.1371/journal.pone.0219309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Sommerburg O, Hämmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, Stahl M. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants (Basel) 2021;10:483. [PMID: 33808590 DOI: 10.3390/antiox10030483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, Shunova A, Hector A, Riethmüller J. Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact. Nutrients 2019;11:E656. [PMID: 30889905 DOI: 10.3390/nu11030656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gentzsch M, Mall MA. Ion Channel Modulators in Cystic Fibrosis. Chest. 2018;154:383-393. [PMID: 29750923 DOI: 10.1016/j.chest.2018.04.036] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
16 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
17 Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, Castellani C. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci 2020;21:E5882. [PMID: 32824306 DOI: 10.3390/ijms21165882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
18 Wu AC, Kiley JP, Noel PJ, Amur S, Burchard EG, Clancy JP, Galanter J, Inada M, Jones TK, Kropski JA, Loyd JE, Nogee LM, Raby BA, Rogers AJ, Schwartz DA, Sin DD, Spira A, Weiss ST, Young LR, Himes BE. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. Am J Respir Crit Care Med 2018;198:e116-36. [PMID: 30640517 DOI: 10.1164/rccm.201810-1895ST] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 9.7] [Reference Citation Analysis]
19 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
20 Loukou I, Petrocheilou A, Moustaki M, Katsagoni CN, Douros K. Cystic fibrosis drug approved for patients aged 6-11 years worked well in clinical practice. Acta Paediatr 2021;110:228-9. [PMID: 32762058 DOI: 10.1111/apa.15519] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Mitash N, Mu F, Donovan JE, Myerburg MM, Ranganathan S, Greene CM, Swiatecka-Urban A. Transforming Growth Factor-β1 Selectively Recruits microRNAs to the RNA-Induced Silencing Complex and Degrades CFTR mRNA under Permissive Conditions in Human Bronchial Epithelial Cells. Int J Mol Sci 2019;20:E4933. [PMID: 31590401 DOI: 10.3390/ijms20194933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gabel ME, Fox CK, Grimes RA, Lowman JD, McDonald CM, Stallings VA, Michel SH. Overweight and cystic fibrosis: An unexpected challenge. Pediatr Pulmonol 2021. [PMID: 34738328 DOI: 10.1002/ppul.25748] [Reference Citation Analysis]
23 Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH, Majoor CJ, Maitland-van der Zee AH, Mathôt RAA, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) research group. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. Ther Drug Monit 2021;43:555-63. [PMID: 33165217 DOI: 10.1097/FTD.0000000000000829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fleischer A, Vallejo-Díez S, Martín-Fernández JM, Sánchez-Gilabert A, Castresana M, Del Pozo A, Esquisabel A, Ávila S, Castrillo JL, Gaínza E, Pedraz JL, Viñas M, Bachiller D. iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation. Mol Ther Methods Clin Dev 2020;17:858-70. [PMID: 32373648 DOI: 10.1016/j.omtm.2020.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
25 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
26 Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL. CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros 2019;18:22-34. [PMID: 29934203 DOI: 10.1016/j.jcf.2018.05.004] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 24.0] [Reference Citation Analysis]
27 Brewington JJ, Filbrandt ET, LaRosa FJ 3rd, Moncivaiz JD, Ostmann AJ, Strecker LM, Clancy JP. Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies. JCI Insight 2018;3:99385. [PMID: 29997283 DOI: 10.1172/jci.insight.99385] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
28 Bokov P, Gerardin M, Le Clainche L, Houdouin V, Delclaux C. Impulse oscillometry indices to detect an abnormal lung clearance index in childhood cystic fibrosis. Pediatr Pulmonol 2021;56:3752-7. [PMID: 34449977 DOI: 10.1002/ppul.25649] [Reference Citation Analysis]
29 Bayfield KJ, Alton E, Irving S, Bush A, Davies JC. Nitrogen offset in N2 multiple washout method. ERJ Open Res 2020;6:00043-2020. [PMID: 32201685 DOI: 10.1183/23120541.00043-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Clancy JP. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 2018;53:S4-S11. [PMID: 30289627 DOI: 10.1002/ppul.24157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
32 Arnaud F, Stremler-Le Bel N, Reynaud-Gaubert M, Mancini J, Gaubert JY, Gorincour G. Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor. J Clin Med 2021;10:1999. [PMID: 34066942 DOI: 10.3390/jcm10091999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Sutharsan S, Naehrig S, Mellies U, Sieder C, Ziegler J. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa. BMC Pulm Med 2020;20:167. [PMID: 32532226 DOI: 10.1186/s12890-020-01201-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Stylemans D, Darquenne C, Schuermans D, Verbanck S, Vanderhelst E. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)00098-9. [PMID: 33832855 DOI: 10.1016/j.jcf.2021.03.016] [Reference Citation Analysis]
35 Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals (Basel) 2021;14:928. [PMID: 34577628 DOI: 10.3390/ph14090928] [Reference Citation Analysis]
36 Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, Kulmatycki K, Yates DP, Danahay H, Gosling M, Rowlands DJ, Grant SS. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial. Int J Chron Obstruct Pulmon Dis 2020;15:2399-409. [PMID: 33116455 DOI: 10.2147/COPD.S257474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
37 Rubin JL, O'Callaghan L, Pelligra C, Konstan MW, Ward A, Ishak JK, Chandler C, Liou TG. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Ther Adv Respir Dis 2019;13:1753466618820186. [PMID: 30803355 DOI: 10.1177/1753466618820186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
38 Perrem L, Ratjen F. Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis. Front Pharmacol 2020;11:576293. [PMID: 33013419 DOI: 10.3389/fphar.2020.576293] [Reference Citation Analysis]
39 Clunes LA, McMillan-Castanares N, Mehta N, Mesadieu A, Rodriguez J, Maj M, Clunes MT. Epithelial vectorial ion transport in cystic fibrosis: Dysfunction, measurement, and pharmacotherapy to target the primary deficit. SAGE Open Med 2020;8:2050312120933807. [PMID: 32637102 DOI: 10.1177/2050312120933807] [Reference Citation Analysis]
40 McCravy MS, Quinney NL, Cholon DM, Boyles SE, Jensen TJ, Aleksandrov AA, Donaldson SH, Noone PG, Gentzsch M. Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations. Eur Respir J 2020;56:2000062. [PMID: 32265312 DOI: 10.1183/13993003.00062-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Laucirica DR, Garratt LW, Kicic A. Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity. Front Immunol 2020;11:595. [PMID: 32318073 DOI: 10.3389/fimmu.2020.00595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Spano J, Milla CE. Defining the Clinical Utility of the Lung Clearance Index. Are We There Yet? Am J Respir Crit Care Med 2021;203:937-9. [PMID: 33181036 DOI: 10.1164/rccm.202010-3899ED] [Reference Citation Analysis]
43 Montemayor K, Lechtzin N. The PROSPECT Is Bright for CFTR Modulators. Ann Am Thorac Soc 2021;18:32-3. [PMID: 33385230 DOI: 10.1513/AnnalsATS.202007-881ED] [Reference Citation Analysis]
44 Dagenais RVE, Su VCH, Quon BS. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med 2020;10:E23. [PMID: 33374882 DOI: 10.3390/jcm10010023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Jaques R, Shakeel A, Hoyle C. Novel therapeutic approaches for the management of cystic fibrosis. Multidiscip Respir Med 2020;15:690. [PMID: 33282281 DOI: 10.4081/mrm.2020.690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 . Lumacaftor/ivacaftor for cystic fibrosis. Aust Prescr 2019;42:170-1. [PMID: 31631933 DOI: 10.18773/austprescr.2019.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Estabrooks S, Brodsky JL. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. Int J Mol Sci 2020;21:E452. [PMID: 31936842 DOI: 10.3390/ijms21020452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
48 Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017;377:2024-35. [PMID: 29099333 DOI: 10.1056/NEJMoa1709847] [Cited by in Crossref: 244] [Cited by in F6Publishing: 100] [Article Influence: 48.8] [Reference Citation Analysis]
49 Southern KW, Patel S, Sinha IP, Nevitt SJ. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database Syst Rev 2018;8:CD010966. [PMID: 30070364 DOI: 10.1002/14651858.CD010966.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
50 Talamo Guevara M, McColley SA. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf 2017;16:1305-11. [PMID: 28846049 DOI: 10.1080/14740338.2017.1372419] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
51 Kiedrowski MR, Bomberger JM. Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract. Front Immunol 2018;9:3067. [PMID: 30619379 DOI: 10.3389/fimmu.2018.03067] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
52 Dobra R, Edmondson C, Hughes D, Martin I, Davies JC. Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review. Paediatr Drugs 2018;20:555-66. [PMID: 30328089 DOI: 10.1007/s40272-018-0315-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019. [PMID: 31218221 DOI: 10.1183/23120541.00082-2019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
54 Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis 2019;13:1753466619844424. [PMID: 31027466 DOI: 10.1177/1753466619844424] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
55 Dumas MP, Xia S, Bear CE, Ratjen F. Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine 2021;73:103660. [PMID: 34740114 DOI: 10.1016/j.ebiom.2021.103660] [Reference Citation Analysis]
56 Cheng PC, Alexiou S, Rubenstein RC. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis. Expert Rev Respir Med 2019;13:417-23. [PMID: 30929526 DOI: 10.1080/17476348.2019.1602040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev 2020;12:CD010966. [PMID: 33331662 DOI: 10.1002/14651858.CD010966.pub3] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
58 Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F, Collet C, Mas E, Languepin J, Fayon M, Beaufils F, Mittaine M. Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis. Front Pediatr 2021;9:744705. [PMID: 34869102 DOI: 10.3389/fped.2021.744705] [Reference Citation Analysis]
59 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
60 Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep 2019;9:7234. [PMID: 31076617 DOI: 10.1038/s41598-019-43652-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
61 Woods JC, Wild JM, Wielpütz MO, Clancy JP, Hatabu H, Kauczor HU, van Beek EJR, Altes TA. Current state of the art MRI for the longitudinal assessment of cystic fibrosis. J Magn Reson Imaging 2020;52:1306-20. [PMID: 31846139 DOI: 10.1002/jmri.27030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
62 Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros 2020;19:677-87. [PMID: 32522463 DOI: 10.1016/j.jcf.2020.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
63 Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol. 2019;10:121. [PMID: 30873022 DOI: 10.3389/fphar.2019.00121] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
64 Balfour-Lynn IM. Clinical papers of the year 2018 - Cystic fibrosis. Paediatr Respir Rev 2020;33:58-61. [PMID: 31053358 DOI: 10.1016/j.prrv.2019.03.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]